ENPICOM
ENPICOM receives ISO 27001:2013 certification
Being ISO 27001:2013 certified means that ENPICOM has a world-class security system in place. We are committed to pursuing excellence in our business operations, technology, and customer experience.
Category: All
Accurate developability assessments of antibody candidates with the IGX Platform
Discover how you can use structural modeling to identify antibody liabilities and developability profiles for thousands of sequences at once.
ENPICOM launches versatile display data analysis solution to accelerate antibody selection while maximizing precision
The new IGX-Track App expands the capabilities of the IGX Platform by adding seamless analysis of antibody panning campaigns.
Genovac further enhances its antibody discovery services with the ENPICOM IGX Platform
Genovac, a leading CRO/CMO that discovers, develops, and manufactures antibodies for therapeutic, diagnostic, and research market segments, will utilize ENPICOM’s IGX Platform for antibody discovery workflows.
ENPICOM increases speed and scalability in antibody discovery with Amazon Web Services (AWS)
Now powered by AWS, ENPICOM can further accelerate scientific breakthroughs and enable scientists to harness the latest scientific advances.
Phylogenetic analysis of BCR repertoires: Benefits, challenges, and considerations
Discover how you can perform advanced phylogenetic analysis, understand B cell lineages and the affinity maturation process to expand your antibody candidate pool.
ENPICOM secures Series B funding to scale up operations to meet the high demand for its antibody discovery SaaS Platform
ENPICOM has secured funding from BOP Capital to support the growth of their unique SaaS platform for therapeutic antibody discovery.
ENPICOM participates in Inno4vac, a European new public-private partnership to innovate vaccine development
Inno4vac is a new interdisciplinary project funded by the Innovative Medicines Initiative 2 that aims to foster health innovation by incorporating scientific and technological breakthrough from the academic and biotech sectors into industry.
ENPICOM introduces a powerful liability prediction solution to de-risk antibody development
The IGX Platform empowers researchers to accurately predict exposed liabilities for thousands of sequences at the same time using high-throughput structural modeling.
ENPICOM is featured among the top 50 fastest growing Data Science SMEs in the Netherlands
The Florijnz Data Science Top 50 report is out! We’re excited to be recognized as one of the fastest-growing players in the Data Science market for small and medium-sized enterprises in the Netherlands.